$23.90
-1.20 (-4.78%)
Open$24.77
Previous Close$25.10
Day High$24.99
Day Low$22.70
52W High$43.66
52W Low$15.93
Volume—
Avg Volume288.8K
Market Cap526.60M
P/E Ratio—
EPS$-3.16
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+5.2% upside
Current
$23.90
$23.90
Target
$25.14
$25.14
$17.03
$25.14 avg
$37.02
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 808.7K | 64.19M | 65.56M |
| Net Income | -65,643,442 | 8.40M | 8.13M |
| Profit Margin | -8,123.7% | 13.1% | 12.4% |
| EBITDA | -70,237,992 | 15.55M | 13.35M |
| Free Cash Flow | — | 10.13M | 9.92M |
| Rev Growth | — | +4.7% | +24.1% |
| Debt/Equity | 0.00 | 0.89 | 0.79 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |